Tourmaline Bio, Inc. (TRML)

Tourmaline Bio Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Selling, General & Admin	22.58	22.75	13.04	2.18	0.69
Research & Development	75.87	66.99	32.37	17.53	0.21
Operating Expenses	98.45	89.73	45.41	19.7	0.9
Operating Income	-98.45	-89.73	-45.41	-19.7	-0.9
Interest & Investment Income	5.7	5.7	0.2	-	-
Other Non Operating Income (Expenses)	2.2	3.14	2.55	-	-
EBT Excluding Unusual Items	-90.55	-80.89	-42.66	-19.7	-0.9
Gain (Loss) on Sale of Investments	7.68	7.68	0.54	-	-
Pretax Income	-82.87	-73.21	-42.12	-19.7	-0.9
Net Income	-82.87	-73.21	-42.12	-19.7	-0.9
Net Income to Common	-82.87	-73.21	-42.12	-19.7	-0.9
Shares Outstanding (Basic)	26	25	5	1	11
Shares Outstanding (Diluted)	26	25	5	1	11
Shares Change (YoY)	144.29%	433.98%	441.28%	-91.94%	-
EPS (Basic)	-3.22	-2.89	-8.87	-22.46	-0.08
EPS (Diluted)	-3.22	-2.89	-8.87	-22.46	-0.08
Free Cash Flow	-84.04	-77.27	-28.14	-6.53	-
Free Cash Flow Per Share	-3.26	-3.05	-5.93	-7.44	-
EBITDA	-98.41	-89.69	-45.38	-19.7	-
D&A For EBITDA	0.04	0.04	0.03	0.01	-
EBIT	-98.45	-89.73	-45.41	-19.7	-0.9

Updated May 2, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q